Kim A, Jeon S, Kim H, Hong H, Yoon Y, Lee B
Nutrients. 2024; 16(17).
PMID: 39275335
PMC: 11396792.
DOI: 10.3390/nu16173021.
Lee H, Jeon H, Jang J, Lee Y, Shin Y, Nahm D
J Allergy Clin Immunol Glob. 2024; 3(2):100245.
PMID: 38577481
PMC: 10992700.
DOI: 10.1016/j.jacig.2024.100245.
Sitko K, Starke M, Tukaj S
Cell Stress Chaperones. 2023; 28(6):935-942.
PMID: 37851180
PMC: 10746637.
DOI: 10.1007/s12192-023-01387-0.
Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan R, Bangert C
Clin Transl Allergy. 2023; 13(9):e12299.
PMID: 37746794
PMC: 10500634.
DOI: 10.1002/clt2.12299.
Caffarelli C, Giannetti A, Gianni G, Ricci G
Front Med (Lausanne). 2023; 10:1214963.
PMID: 37654660
PMC: 10466416.
DOI: 10.3389/fmed.2023.1214963.
Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above >1500 IU/mL.
Menzella F, Just J, Schwab Sauerbeck I, Mailaender C, Saccheri F, Thonnelier C
World Allergy Organ J. 2023; 16(6):100787.
PMID: 37332525
PMC: 10276275.
DOI: 10.1016/j.waojou.2023.100787.
Degranulation of Mast Cells as a Target for Drug Development.
Yang B, Kim A, Lee D, An S, Shim Y, Jang M
Cells. 2023; 12(11).
PMID: 37296626
PMC: 10253146.
DOI: 10.3390/cells12111506.
Tailored treatments in inborn errors of immunity associated with atopy (IEIs-A) with skin involvement.
Giancotta C, Colantoni N, Pacillo L, Santilli V, Amodio D, Manno E
Front Pediatr. 2023; 11:1129249.
PMID: 37033173
PMC: 10073443.
DOI: 10.3389/fped.2023.1129249.
The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment.
Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E
Cell Mol Immunol. 2023; 20(5):448-474.
PMID: 36928371
PMC: 10203371.
DOI: 10.1038/s41423-023-00992-4.
Self-reactive IgE and anti-IgE therapy in autoimmune diseases.
Olewicz-Gawlik A, Kowala-Piaskowska A
Front Pharmacol. 2023; 14:1112917.
PMID: 36755957
PMC: 9899859.
DOI: 10.3389/fphar.2023.1112917.
Successful management of chronic urticaria and food allergies in a pediatric population using integrative traditional Chinese medicine therapy: a case series.
Fan X, McKnight T, Neshiwat J, Park S, Chung D, Li X
Clin Mol Allergy. 2022; 20(1):12.
PMID: 36434719
PMC: 9700962.
DOI: 10.1186/s12948-022-00175-y.
Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy.
An S, Yang B, Jang G, Kim D, Kim J, Oh S
Nat Commun. 2022; 13(1):5669.
PMID: 36167830
PMC: 9515155.
DOI: 10.1038/s41467-022-33176-1.
Roles of Mast Cells in Cutaneous Diseases.
Numata T, Harada K, Nakae S
Front Immunol. 2022; 13:923495.
PMID: 35874756
PMC: 9298983.
DOI: 10.3389/fimmu.2022.923495.
Omalizumab for STAT3 Hyper-IgE Syndromes in Adulthood: A Case Report and Literature Review.
Lan J, Zhang Y, Song M, Cai S, Luo H, Ouyang R
Front Med (Lausanne). 2022; 9:835257.
PMID: 35602476
PMC: 9114644.
DOI: 10.3389/fmed.2022.835257.
Expert consensus on the use of omalizumab in chronic urticaria in China.
Zhao Z, Cai T, Chen H, Chen L, Chen Y, Gao X
World Allergy Organ J. 2021; 14(11):100610.
PMID: 34934470
PMC: 8654989.
DOI: 10.1016/j.waojou.2021.100610.
Consensus Update for Systemic Treatment of Atopic Dermatitis.
Lee J, Kim J, Park G, Bae J, Byun J, Shin M
Ann Dermatol. 2021; 33(6):497-514.
PMID: 34858001
PMC: 8577915.
DOI: 10.5021/ad.2021.33.6.497.
Update on the Pathogenesis and Therapy of Atopic Dermatitis.
Li H, Zhang Z, Zhang H, Guo Y, Yao Z
Clin Rev Allergy Immunol. 2021; 61(3):324-338.
PMID: 34338977
DOI: 10.1007/s12016-021-08880-3.
Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence.
Wollenberg A, Thomsen S, Lacour J, Jaumont X, Lazarewicz S
World Allergy Organ J. 2021; 14(3):100519.
PMID: 33815652
PMC: 8005850.
DOI: 10.1016/j.waojou.2021.100519.
Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect.
Ratchataswan T, Banzon T, Thyssen J, Weidinger S, Guttman-Yassky E, Phipatanakul W
J Allergy Clin Immunol Pract. 2021; 9(3):1053-1065.
PMID: 33685604
PMC: 7951162.
DOI: 10.1016/j.jaip.2020.11.034.
Effectiveness and Response Predictors of Omalizumab in Treating Patients with Seasonal Allergic Rhinitis: A Real-World Study.
Ma T, Wang H, Wang X
J Asthma Allergy. 2021; 14:59-66.
PMID: 33519214
PMC: 7837594.
DOI: 10.2147/JAA.S288952.
